Patent ID: 9724312
Date: 2017-08-08
CPC Classifications: A61K,A61P

Claim:
1. A method for ameliorating or treating a retinal disease selected from the group consisting of retinitis pigmentosa and age-related macular degeneration, the method comprising a step of bringing an effective amount of a composition comprising geranylgeranylacetone into contact with retinal pigment epithelial cells of a patient with the retinal disease, wherein the geranylgeranylacetone is selected from the group consisting of: (a) a mixture of at least two geometric isomers of geranylgeranylacetone, wherein the mixture contains at least 80% by weight or more of (5E,9E,13E)-geranylgeranylacetone relative to the total weight of the mixture, and (b) (5E,9E,13E)-geranylgeranylacetone, thereby ameliorating or treating the retinal disease, wherein the composition comprises a content of geranylgeranylacetone of 0.1 to 10% by weight when the composition is an ophthalmic composition in the form of a liquid, a fluid, a gel, or a semi-solid, and wherein a daily dose of the geranylgeranylacetone is 5 to 5000 mg when the composition is an oral agent.